Non-coding RNA in endothelial-to-mesenchymal transition

Melanie S. Hulshoff, Gonzalo del Monte-Nieto, Jason Kovacic, Guido Krenning

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Endothelial-to-mesenchymal transition (EndMT) is the process wherein endothelial cells lose their typical endothelial cell markers and functions and adopt a mesenchymal-like phenotype. EndMT is required for development of the cardiac valves, the pulmonary and dorsal aorta, and arterial maturation, but activation of the EndMT programme during adulthood is believed to contribute to several pathologies including organ fibrosis, cardiovascular disease, and cancer. Non-coding RNAs, including microRNAs, long non-coding RNAs, and circular RNAs, modulate EndMT during development and disease. Here, we review the mechanisms by which non-coding RNAs facilitate or inhibit EndMT during development and disease and provide a perspective on the therapeutic application of non-coding RNAs to treat fibroproliferative cardiovascular disease.

Original languageEnglish
Pages (from-to)1716-1731
Number of pages16
JournalCardiovascular Research
Volume115
Issue number12
DOIs
Publication statusPublished - 1 Oct 2019

Keywords

  • Cardiac development
  • Cardiovascular disease
  • Endothelial-mesenchymal transition (EndMT)
  • Non-coding RNA
  • Plasticity

Cite this

Hulshoff, Melanie S. ; del Monte-Nieto, Gonzalo ; Kovacic, Jason ; Krenning, Guido. / Non-coding RNA in endothelial-to-mesenchymal transition. In: Cardiovascular Research. 2019 ; Vol. 115, No. 12. pp. 1716-1731.
@article{189090a8ef7b4c7690c3b5bb7d3fe8d4,
title = "Non-coding RNA in endothelial-to-mesenchymal transition",
abstract = "Endothelial-to-mesenchymal transition (EndMT) is the process wherein endothelial cells lose their typical endothelial cell markers and functions and adopt a mesenchymal-like phenotype. EndMT is required for development of the cardiac valves, the pulmonary and dorsal aorta, and arterial maturation, but activation of the EndMT programme during adulthood is believed to contribute to several pathologies including organ fibrosis, cardiovascular disease, and cancer. Non-coding RNAs, including microRNAs, long non-coding RNAs, and circular RNAs, modulate EndMT during development and disease. Here, we review the mechanisms by which non-coding RNAs facilitate or inhibit EndMT during development and disease and provide a perspective on the therapeutic application of non-coding RNAs to treat fibroproliferative cardiovascular disease.",
keywords = "Cardiac development, Cardiovascular disease, Endothelial-mesenchymal transition (EndMT), Non-coding RNA, Plasticity",
author = "Hulshoff, {Melanie S.} and {del Monte-Nieto}, Gonzalo and Jason Kovacic and Guido Krenning",
year = "2019",
month = "10",
day = "1",
doi = "10.1093/cvr/cvz211",
language = "English",
volume = "115",
pages = "1716--1731",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "12",

}

Non-coding RNA in endothelial-to-mesenchymal transition. / Hulshoff, Melanie S.; del Monte-Nieto, Gonzalo; Kovacic, Jason; Krenning, Guido.

In: Cardiovascular Research, Vol. 115, No. 12, 01.10.2019, p. 1716-1731.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Non-coding RNA in endothelial-to-mesenchymal transition

AU - Hulshoff, Melanie S.

AU - del Monte-Nieto, Gonzalo

AU - Kovacic, Jason

AU - Krenning, Guido

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Endothelial-to-mesenchymal transition (EndMT) is the process wherein endothelial cells lose their typical endothelial cell markers and functions and adopt a mesenchymal-like phenotype. EndMT is required for development of the cardiac valves, the pulmonary and dorsal aorta, and arterial maturation, but activation of the EndMT programme during adulthood is believed to contribute to several pathologies including organ fibrosis, cardiovascular disease, and cancer. Non-coding RNAs, including microRNAs, long non-coding RNAs, and circular RNAs, modulate EndMT during development and disease. Here, we review the mechanisms by which non-coding RNAs facilitate or inhibit EndMT during development and disease and provide a perspective on the therapeutic application of non-coding RNAs to treat fibroproliferative cardiovascular disease.

AB - Endothelial-to-mesenchymal transition (EndMT) is the process wherein endothelial cells lose their typical endothelial cell markers and functions and adopt a mesenchymal-like phenotype. EndMT is required for development of the cardiac valves, the pulmonary and dorsal aorta, and arterial maturation, but activation of the EndMT programme during adulthood is believed to contribute to several pathologies including organ fibrosis, cardiovascular disease, and cancer. Non-coding RNAs, including microRNAs, long non-coding RNAs, and circular RNAs, modulate EndMT during development and disease. Here, we review the mechanisms by which non-coding RNAs facilitate or inhibit EndMT during development and disease and provide a perspective on the therapeutic application of non-coding RNAs to treat fibroproliferative cardiovascular disease.

KW - Cardiac development

KW - Cardiovascular disease

KW - Endothelial-mesenchymal transition (EndMT)

KW - Non-coding RNA

KW - Plasticity

UR - http://www.scopus.com/inward/record.url?scp=85072588360&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvz211

DO - 10.1093/cvr/cvz211

M3 - Article

VL - 115

SP - 1716

EP - 1731

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 12

ER -